Laser Dosage in MicroPulse TransScleral CycloPhotocoagulation

Stopped early · Not applicable

Conditions studied: Glaucoma

In brief

This is a prospective study to evaluate the clinical outcome of varying doses of Micropulse TransScleral CycloPhotocoagulation (MP-TSCPC) laser in patients with glaucoma. The study will assess documented complication rates, changes in visual acuity after the procedure, changes in intraocular pressures and medication drop usage, and need for subsequent treatments (including further laser or surgery).

Key facts

Study ID

NCT04709679

Run by

State University of New York at Buffalo

People needed

6

Starts

2021-01-01

Expected to finish

2021-10-11

Last updated by the study team

2022-07-01

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Decision to treat by MP-TSCPC Laser
• Patients diagnosed with Glaucoma
• Patients aged 18 years old and above
• Glaucoma that is inadequately controlled on medical therapy
• Patients with primary open angle glaucoma with or without previously failed trabeculectomy or other aqueous drainage surgical procedures

You may not qualify if…

• Patients age less than 18 years
• Patients unable or unwilling to provide informed consent to participate in the study
• Patients potentially unavailable for follow up visits
• Patients with significant scleral thinning
• Patients with ocular infection, inflammation or intraocular surgery in the study eye 2 months prior to enrollment in the study
• Albino patients that have no iris pigmentation

Where it is running

• The Ira G. Ross Eye Institute — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.